acrivastine (Semprex)

01/01/1989 - "A total of 20 patients with a diagnosis of chronic idiopathic urticaria were entered into a fully randomized, double-blind, crossover study to investigate the efficacy of 8 mg acrivastine versus 4 mg chlorpheniramine three times daily. "
01/01/1989 - "Twenty patients of mean age 41.3 years, with a diagnosis of chronic idiopathic urticaria were assessed in a fully randomized, double-blind, crossover study to investigate the efficacy of acrivastine at two doses (8 mg and 4 mg) versus 1 mg clemastine and placebo, given three times per day. "
01/01/1989 - "A total of 21 patients with a diagnosis of chronic idiopathic urticaria were assessed in a fully randomized, double-blind, crossover study to investigate the efficacy of 8 mg acrivastine versus 20 mg hydroxyzine and placebo administered three times daily. "
01/01/1989 - "Patients (n = 56) with a diagnosis of chronic idiopathic urticaria were assessed in a fully randomized, double-blind, crossover study to investigate the efficacy of acrivastine at two doses (8 and 4 mg) versus 60 mg terfenadine and placebo administered three times daily. "
01/01/1989 - "A comparison of acrivastine versus chlorpheniramine in the treatment of chronic idiopathic urticaria."

01/01/1989 - "Acrivastine was both well tolerated and effective in the treatment of seasonal allergic rhinitis."
01/01/1989 - "Unequivocal evidence of the efficacy of 8 mg acrivastine three times daily for the control of symptoms of seasonal allergic rhinitis has been provided by 11 placebo-controlled studies involving almost 1000 patients. "
01/01/1989 - "Acrivastine in two doses compared with placebo in a multicentre, parallel group study for the treatment of seasonal allergic rhinitis."
11/01/1988 - "One study on 31 patients found both 4 and 8 mg acrivastine given three times daily to be significantly better than placebo for alleviating hay fever. "
01/01/1989 - "Acrivastine is effective and well tolerated over prolonged periods (up to 52 days) for the treatment of seasonal allergic rhinitis."

09/01/1994 - "Efficacy of acrivastine in the treatment of allergic rhinitis during natural pollen exposure: onset of action."
01/01/1989 - "This comprehensive review of clinical experience with acrivastine in allergic rhinitis considers all currently available data both published and, as yet, unpublished. "
01/01/1989 - "Acrivastine in allergic rhinitis: a review of clinical experience."
05/01/1996 - "These findings in a large clinical trial demonstrate (1) the efficacy of acrivastine and (2) that each component of the combination of acrivastine 8 mg plus pseudoephedrine HCl 60 mg contributes to the overall efficacy, thereby supporting the conclusion that the combination is rational, safe, and effective for the treatment of allergic rhinitis."
02/01/1996 - "These findings in a large clinical trial demonstrate that each component of the combination of acrivastine 8 mg plus pseudoephedrine HCl 60 mg contributes to the overall efficacy, thereby supporting the conclusion that the combination is rational, safe, and effective for the treatment of allergic rhinitis."

01/01/1984 - "Both doses of BW 825C were found to be highly effective and significantly better than placebo in controlling signs and symptoms of urticaria. "
01/01/1989 - "Both acrivastine and hydroxyzine were found to be effective, and significantly better than placebo, in controlling signs and symptoms of urticaria. "
01/01/1989 - "Both acrivastine and chlorpheniramine were found to be effective in relieving the signs and symptoms of urticaria. "
01/01/1988 - "Both acrivastine and hydroxyzine were shown to be effective and well tolerated in the treatment of cholinergic urticaria. "
09/01/1999 - "Our results indicate that a single dose of cetirizine provides a more effective and long acting suppression on wheal and flare reactions in urticaria when compared to acrivastine and loratadine."

01/01/1994 - "Ten subjects with a well-documented allergy to pollen received single doses of 8 mg of acrivastine and placebo according to a randomized, double-blind, placebo-controlled, crossover treatment design. "
03/01/1996 - "Atopic subjects with allergies treated with acrivastine + pseudoephedrine learned as well as normal subjects."
05/01/1996 - "Over the 2-week period, the combination of acrivastine plus pseudoephedrine was significantly more effective than (1) acrivastine, pseudoephedrine, and placebo (P < .001) for relief of all symptoms; (2) pseudoephedrine (P < .001) for relieving allergy symptoms, ie, running nose, sneezing, itchy nose/throat and tearing; and (3) acrivastine (P < .001) for reducing nasal congestion. "
02/01/1996 - "The objective of the study was to demonstrate that both acrivastine and pseudoephedrine share in the efficacy of the combination in relieving allergy symptoms in patients sensitive to ragweed pollen. "
01/01/2006 - "A randomized, double-blind, placebo-controlled study was performed in which Ze 339 was compared to acrivastine, a short-acting antihistamine, in 8 patients with respiratory allergy and in 10 nonatopic, healthy volunteers. "